Electronic Acl	knowledgement Receipt			
EFS ID:	1096881			
Application Number:	09701140			
Confirmation Number:	6011			
Title of Invention:	PHARMACEUTICAL COMPOSITIONS COMPRISING AN AMPHOTERIC SURFACTANT AN ALKOXYLATED CETYL ALCOHOL AND A POLAR-DRUG			
First Named Inventor:	Brian Hawtin			
Correspondence Address:	Mark J Burns - 1130 TCF Tower 121 South Eighth Street Minneapolis MN 55402 US 6123398300			
Filer:	Mark James Burns/Stacey Seidel			
Filer Authorized By:	Mark James Burns			
Attorney Docket Number:	2000-0702.OR			
Receipt Date:	29-JUN-2006			
Filing Date:	21-NOV-2000			
Time Stamp:	11:13:09			
Application Type:	U.S. National Stage under 35 USC 371			
International Application Number:				
Payment information:				

no

Submitted with Payment

## File Listing:

	umber	Document Description	File Name	File Size(Bytes)	Part	Pages
	1	Request for status of Application	20000702StatusInq.pdf	121153	no	1
War	nings:					
Info	rmation	<u> </u>				

Multi

121153

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

Total Files Size (in bytes):

## New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

## National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.